Clinical trials: Deglutition Disorder
Mitral Valve Regurgitation
Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
The purpose of this study is to test the safety and device performance of the Mitralign system ("MPAS") to treat functional mitral valve regurgitation.
- Trial name
- ALIGN (NCT01740583)
- Testing
- percutaneous annuloplasty
- Where
- 8 sites in Colombia, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Mitralign, Inc.
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251758
- Testing
- Dexlansoprazole MR
- Where
- 99 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, Hiatal Hernia
Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study
The objective of the study is to evaluate the relative merits, safety and effectiveness of the EsophyX transoral device in performing an advanced TIF procedure in patients with "troublesome symptoms" as defined by the Montreal…
- Trial name
- RESPECT (NCT01136980)
- Testing
- TIF Transoral Fundoplication
- Where
- 9 sites in United States
- Volunteers
- 129 people
- Sponsor
- EndoGastric Solutions
Gastroesophageal Reflux
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease…
- Trial name
- NCT02030925
- Testing
- IW-3718
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease (GERD)
Retrospective Observational Study on GERD Management in General Hospitals in Korea
A RetrospectiVe ObservatIoNal Study of a CurrEnt Status and its Management of GERD (GastroEsophageal Reflux Disease) in General HOspitals in Korea
- Trial name
- VINCERO (NCT06974903)
- Where
- South Korea
- Volunteers
- 13,750 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastroesophageal Reflux
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.
- Trial name
- NCT00229424
- Testing
- Lafutidine, Famotidine
- Where
- Japan
- Volunteers
- 325 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
GERD
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
This is a cross-sectional study of symptom burden and clinical management. A subset of patients who have attended the Primary Care (PC) office with reflux symptoms during a retrospective period of 4 months (Index Visit) are…
- Trial name
- RANGE (NCT00634023)
- Where
- 15 sites in Canada
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Heartburn
Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn
Remote un-controlled trial to evaluate the tolerability of MHS-1031 and separately the tolerability of the formulated placebo in subjects with heartburn.
- Trial name
- NCT05363618
- Testing
- Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)
- Where
- United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Microbiome Health Sciences
Gastroesophageal Reflux Disease (GERD)
A Post-Approval Study of the LINX® Reflux Management System
A Post-Approval Study of the LINX® Reflux Management System in a prospective, multicenter, single-arm study, with patients as their own control to monitor the safety and efficacy of the LINX implant procedure and device in a…
- Trial name
- NCT01940185
- Testing
- LINX device
- Where
- 19 sites in United States
- Volunteers
- 200 people
- Sponsor
- Torax Medical Incorporated
GERD, Acid Reflux, Treatment
Omega Cuff for GERD Feasibility Study
This clinical feasibility study is to evaluate the performance of the Omega-Cuff in the treatment of acid reflux for up to 15 patients with a 1-year follow-up period.
- Trial name
- NCT04793035
- Testing
- Omega-Cuff
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Aplos Medical
Gastroesophageal Reflux, Esophagitis
Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis
The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.
- Trial name
- NCT00195208
- Testing
- Pantoprazole for approximately 9 weeks
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Heartburn, Gastroesophageal Reflux Disease
Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients
The purpose of this study is to determine the efficacy and safety of dexlansoprazole compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in Chinese participants with symptomatic non-erosive…
- Trial name
- NCT02873689
- Testing
- Dexlansoprazole
- Where
- 25 sites in China
- Volunteers
- 217 people
- Sponsor
- Takeda
GERD
PK/PD Clinical Trial of YYD601 in Healthy Adult Male
A dose block-randomized, open-label, parallel clinical trial
- Trial name
- NCT03558477
- Testing
- YYD601 1, YYD601 2, YYD601 3
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Gastroesophageal Reflux Disease
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to participants who have GERD and continue to experience GERD symptoms while receiving once-daily…
- Trial name
- NCT02637557
- Testing
- IW-3718, PPI
- Where
- 62 sites in United States
- Volunteers
- 282 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Gastroesophageal Reflux
Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD
The purpose of this study is to determine whether or not consistent drug levels can be achieved in infants with presumed Gastroesophageal Reflux Disease.
- Trial name
- NCT00362609
- Testing
- pantoprazole
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Irritable Bowel Syndrome, Gallstone Disease
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in…
- Conditions
- Irritable Bowel Syndrome, Gallstone Disease, GERD, Biliary Dyskinesia
- Trial name
- NCT07421011
- Testing
- Trimedat®
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Laryngopharyngeal Reflux (LPR)
Quality of Life Validation in Laryngitis
The primary purpose of this study was to establish the psychometric properties of a new disease specific Quality of Life questionnaire, the LPR-HRQL.
- Trial name
- NCT00641264
- Testing
- Omeprazole, Quality of Life questionnaire
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response
To characterize the burden of disease in GERD patients of prescription therapy'
- Trial name
- NCT00392002
- Testing
- Esomeprazole
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Gastric Acid Suppression, Proton Pump Inhibitors
Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium
This study will assess the effectiveness of Nexium at alleviating upper GI symptoms in subjects and evaluate with which treatment regimen and on which indications acid suppression with isomeric proton pump inhibitor is used in…
- Trial name
- NCT01130935
- Where
- 14 sites in Albania
- Volunteers
- 491 people
- Sponsor
- AstraZeneca